To the full analysis
Edwards Lifesciences stock: growth
EWEdwards Lifesciences reported $6.07B in revenue for fiscal 2025, up 11.5% on the prior year, up 10.8% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
9.7%
per year from 2006 to 2025, per share 10.8%
Earnings (Annual rate)
11.7%
per year from 2006 to 2025, per share 12.7%
Free cash flow (Annual rate)
11.4%
per year from 2006 to 2025, per share 12.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.7% | 9.3% | 9.7% |
| Revenue per share | 8.0% | 10.4% | 10.8% |
| Earnings | 5.4% | 8.1% | 11.7% |
| Earnings per share | 6.9% | 9.1% | 12.7% |
| Free cash flow | 15.6% | 11.7% | 11.4% |
| Free cash flow per share | 17.0% | 12.8% | 12.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.04B | $130.5M | $171.4M |
| 2007 | $1.09B | $113M | $147.7M |
| 2008 | $1.24B | $128.9M | $75.2M |
| 2009 | $1.32B | $229.1M | $101.3M |
| 2010 | $1.45B | $218M | $188.4M |
| 2011 | $1.68B | $236.7M | $223.9M |
| 2012 | $1.9B | $293.2M | $246.1M |
| 2013 | $2.05B | $391.7M | $362.6M |
| 2014 | $2.32B | $811.1M | $928.6M |
| 2015 | $2.49B | $494.9M | $443.2M |
| 2016 | $2.96B | $569.5M | $487M |
| 2017 | $3.44B | $622.1M | $825.2M |
| 2018 | $3.72B | $722.2M | $685.1M |
| 2019 | $4.35B | $1.05B | $901M |
| 2020 | $4.39B | $823.4M | $647M |
| 2021 | $5.23B | $1.5B | $1.4B |
| 2022 | $5.38B | $1.52B | $953.4M |
| 2023 | $5.01B | $1.4B | $629.5M |
| 2024 | $5.44B | $4.17B | $289.9M |
| 2025 | $6.07B | $1.07B | $1.34B |
Revenue by segment
How Edwards Lifesciences Corporation makes its money and how that has shifted. Names are as the company reports them.
- Transcatheter Heart Valves74%
- Surgical Heart Valve Therapy17%
- Transcatheter Mitral And Tricuspid Therapies9%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Transcatheter Heart Valves | $4.11B | $4.49B | 74% |
| Surgical Heart Valve Therapy | $981.3M | $1.03B | 17% |
| Transcatheter Mitral And Tricuspid Therapies | $352.1M | $550.6M | 9.1% |
| Total revenue | $5.44B | $6.07B | 100% |
Revenue by region
Where Edwards Lifesciences Corporation generates its revenue.
- United States58%
- Europe25%
- Rest of world11%
- Japan6%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $3.21B | $3.54B | 58.4% |
| Europe | $1.32B | $1.52B | 25% |
| Rest of world | $572M | $652.3M | 10.8% |
| Japan | $339.8M | $354.7M | 5.8% |
| Total revenue | $5.44B | $6.07B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.